Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors
2 Oncotelic inks deal to acquire Parkinson's disease drug candidate AL-101 from Autotelic
3 AL101 Shows Promising Activity in Recurrent/Metastatic Adenoid Cystic Carcinoma With NOTCH Activating Mutations
4 Ayala Pharmaceuticals Presents Preliminary Clinical Data
5 Ayala (AYLA) falls 4.12% in Light Trading on October 8
6 A Phase II Study of AL101 in People with Triple-Negative Breast Cancer with a Notch Mutation
7 ONCOTELIC THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
8 Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
9 Oncotelic Therapeutics, Inc. (OTLC) Stock Sinks After Acquiring Late-Stage Drug Candidate for Parkinson Disease
10 Trial Testing AL101 in TNBC Doses First Patient
11 Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the
12 56 Biggest Movers From Yesterday
13 Alector, GSK Team Up to Develop 2 ALS Antibody Treatments
14 Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
15 Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment
16 Adenoid Cystic Carcinoma Pipeline Insight Report 2021: Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, AL101, CV8102, Rivoceranib, 9-ING-41
17 Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
18 A Phase II Study of AL101 in Patients with Advanced or Recurrent Adenoid Cystic Carcinoma with Notch Mutations
19 Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class
20 Testing of Potential Parkinson's Therapy AL101 Underway in Phase 1 Trial
21 GSK and Alector to develop antibodies for neurodegenerative diseases
22 GSK and Alector Collaborate on Neurodegenerative Disease mAb Candidates
23 The White Sox Are Down 0-2 in the ALDS, but They’re Not Mediocre
24 Oral Care Products Market 2021 Global Insights and Trends – Johnson & Johnson, GlaxoSmithKline, Dentaid, ColgatePalmolive, Oral-B Laboratories Kao Corp
25 Ayala Pharmaceuticals Reports Third Quarter 2020 Financial
26 Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal
27 Alector Surging on GlaxoSmithKline Deal; Analyst Remains Positive
28 Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
29 ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
30 Ayala Pharmaceuticals Reports Second Quarter 2021 Financial
31 Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
32 Ayala Pharmaceuticals: to initiate Phase II trials in TNBC and T-ALL
33 Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
34 Alector Reports Second Quarter 2021 Financial Results
35 Ayala Pharmaceuticals Announces $25 Million Strategic Financing
36 FDA Grants Novel Agent Orphan Drug Designation for Adenoid Cystic Carcinoma
37 Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update
38 Dosing Begins in Phase 2 Trial of AL001 in ALS With C9orf72 Mutations
39 Gamma Secretase Pipeline Review, H2 2020
40 Ayala Pharmaceuticals Reports Second Quarter 2020 Financial
41 Ayala Pharmaceuticals Presents Phase 1b Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting for AL101, a Pan-Notch Inhibitor, in Patients with Locally Advanced or Metastatic Solid Tumors | Small Molecules | News Channels
42 Ayala Pharmaceuticals to Raise $25 Million in Private Financing
43 Ayala's IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs
44 Alector Provides 2021 Corporate Portfolio Update
45 Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
46 Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance
47 GSK invests in Alector's antibodies for neurodegenerative diseases
48 Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
49 Ayala Pharma nabs AbbVie cancer exec Gordon as CMO
50 Alector: Pioneering Approach In CNS Diseases (NASDAQ:ALEC)
51 GSK Posts Strong Q2 as it Moves toward 2022 Demerger
52 Ayala Pharmaceuticals Signs Deal to Develop and Commercialize AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma
53 Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update
54 Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay
55 Alector: AL001's Phase 3 Initiation/Phase 2 Readout In 2021, $462M In Cash, And AbbVie's Promising Support, +38% Upside
56 Alector bolsters 'immuno-neurology' approach—and GSK's $700M bet—with early phase 2 data
57 Other news to note for Sept. 3, 2021 | 2021-09-03
58 GSK rejects demand from Elliott to overhaul its leadership
59 GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
60 A Proteomics Dive into Cause of Frontotemporal Dementia | ALZFORUM
61 Endoxifen Trial for Invasive Breast Cancer Halted Early After Positive Data
62 Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring
63 Stihl RMA 339 C Review: Great power and flexibility
64 Alector IPO Banks $176M to Test Alzheimer's Drugs in Clinical Trials
65 Jaguar Health rises on Street high target, U.S. cannabis stocks favored at Jefferies – in today's analyst action
66 Tukysa Combo Approved in EU for Advanced HER2-Positive Breast Cancer
67 Alector: Addressing Neuroinflammation In Neurodegenerative Diseases With Potential For A Cure
68 Levels of Progranulin Protein May Affect Parkinson's Severity...
69 Breast Cancer Trial Begins Dosing Zion's HER2 Inhibitor ZN-A-1041
70 IPO Update: Ayala Pharmaceuticals Launches IPO (NASDAQ:AYLA)
71 For World Cancer Day, BIG Highlights Importance of Global Teamwork
72 ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
73 Mindfulness Can Alter Brain's Perception of Pain in Cancer Survivors
74 Margenza Approved in US for Pretreated HER2-positive Breast Cancer
75 Cancer drug developer Ayala Pharmaceuticals raises $17m
76 New York Appellate Court Affirms Decision to Deny Motion to Compel Arbitration in Multi-Billion Dollar Construction Dispute
77 Week Ahead In Pharma: FDA Decisions, Data Readouts, ESMO Presentations
78 Alector Showcases Progress in Immuno-Neurology Clinical
79 Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels
80 Ayala Pharmaceuticals Announces the Appointment of Vered Bisker-Leib, Ph.D. To Its Board of Directors
81 Alector Files for IPO to Fund Studies of Alzheimer's, Dementia Drugs
82 FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer...
83 Carcinoma of Unknown Primary Investigators Pursue Molecular Targets to Tailor Treatments
84 Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic
85 Alector: A Promising Neuro-Immunology Pick For 2020
86 UPDATES: Flooding closes more North Alabama roads
87 Stihl RMA 235 Review
88 In cancer battle, friends ensure no one fights alone
89 Road closures across North Alabama
90 Global Roundup, May 30 | BioSpace